Published • loading... • Updated
AbbVie Bets $10.9 Billion on Apogee in Growth Push
The deal gives AbbVie access to zumilokibart, an experimental treatment tested for atopic dermatitis and asthma, as pharmaceutical companies race to replace blockbuster revenue.
- On Monday, AbbVie announced plans to acquire Apogee Therapeutics for $10.9 billion, marking its largest buyout in more than five years as it strengthens its immunology pipeline.
- Aiming to bolster its inflammatory disease portfolio, AbbVie seeks to maintain market dominance as Humira goes off-patent, building on its $63 billion 2019 Allergan acquisition.
- Apogee's lead candidate, zumilokibart, offers two to four injections annually for atopic dermatitis and asthma, providing a more convenient dosing schedule than Sanofi and Regeneron Pharmaceuticals' Dupixent.
- RBC Capital Markets analyst Brian Abrahams called the buyout an "ideal and sensible outcome," though he noted it occurred "earlier than we would have expected."
- Pharmaceutical dealmaking has surged as companies build portfolios ahead of looming patent expirations, with BioPharma Dive data indicating 2026 totals are on pace to surpass every year since at least 2020.
Insights by Ground AI
Podcasts & Opinions
27 Articles
27 Articles
America's Split Economy: The Boom and the Worker
Deep Analysis · US & Canada Key Facts —The deal. AbbVie agreed to buy Apogee Therapeutics for US$135.11 a share, about US$10.9 billion, funded with debt. —The premium. That was a roughly 49 percent premium over Apogee’s June 18 close — a bet on the next decade, not the next quarter. —The mood. University of […] The post America’s Split Economy: The Boom and the Worker appeared first on The Rio Times.
The Business JournalsReposted by 
NBC Boston
NBC BostonAbbVie paying $10.9B to buy Waltham biotech
·United States
Read Full Article
With its largest acquisition in more than five years, Abbvie strengthens its own pharmaceutical pipeline. The company's acquisition secures access to several active ingredients.
·Düsseldorf, Germany
Read Full Article
Coverage Details
Total News Sources27
Leaning Left2Leaning Right3Center10Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
13%
C 67%
R 20%
Factuality
To view factuality data please Upgrade to Premium
